PharmacyCodes



Teniposido [Inn-Spanish] en es it fr

Teniposido [Inn-Spanish] Brand names, Teniposido [Inn-Spanish] Analogs

Teniposido [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Teniposido [Inn-Spanish] Chemical_Formula

C32H32O13S

Teniposido [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/teniposide.htm

Teniposido [Inn-Spanish] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=110

Teniposido [Inn-Spanish] msds (material safety sheet)

Teniposido [Inn-Spanish] Synthesis Reference

No information avaliable

Teniposido [Inn-Spanish] Molecular Weight

656.655 g/mol

Teniposido [Inn-Spanish] Melting Point

No information avaliable

Teniposido [Inn-Spanish] H2O Solubility

No information avaliable

Teniposido [Inn-Spanish] State

Solid

Teniposido [Inn-Spanish] LogP

1.963

Teniposido [Inn-Spanish] Dosage Forms

Liquid

Teniposido [Inn-Spanish] Indication

Treatment of refractory acute lymphoblastic leukaemia

Teniposido [Inn-Spanish] Pharmacology

Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA.

Teniposido [Inn-Spanish] Absorption

No information avaliable

Teniposido [Inn-Spanish] side effects and Toxicity

No information avaliable

Teniposido [Inn-Spanish] Patient Information

No information avaliable

Teniposido [Inn-Spanish] Organisms Affected

Humans and other mammals